Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
A phase II study to evaluate the safety, pharmacokinetics, and hematopoietic stem cell
mobilization of TG-0054 in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin
disease.
Phase:
Phase 2
Details
Lead Sponsor:
GPCR Therapeutics, Inc. TaiGen Biotechnology Co., Ltd.